Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
December 17, 2015
Mergers & Acquisitions magazine has named Catherine Dargan as one of “The Most Influential Women in Mid-Market M&A.” The inaugural special report celebrates 25 of “the best and the brightest female dealmakers.” Among a group of corporate executives and investment bankers, Ms. Dargan is the only outside counsel recognized.
Ms. Dargan, co-leader of the firm’s Mergers and Acquisitions practice, has broad experience in mergers and acquisitions, both public and private, and partnering arrangements. In addition to structuring and negotiating transactions, Ms. Dargan regularly assists clients with corporate governance, compliance and other matters, and advises on a variety of commercial agreements relating to manufacture, supply, and distribution of core products.
Mergers & Acquisitions highlighted Ms. Dargan’s cross-border transactional work for AstraZeneca, including its $600 million purchase of the U.S. and Canadian rights to Actavis’s branded respiratory business and its $325 million sale of assets and rights to Myalept to Aegerion Pharmaceuticals. The report also noted Ms. Dargan’s work on behalf Ben Venue Laboratories in its $300 million sale of Bedford Laboratories to Hikma Pharmaceuticals.